Clinical Trial Detail

NCT ID NCT02632045
Title Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Kevin Kalinsky
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant

Ribociclib

Age Groups: adult

Additional content available in CKB BOOST